Improving heart health through AI text messaging
Official title: Using Artificially Intelligent Text Messaging Technology to Improve American Heart Association's Life's Essential 8 Health Behaviors: LE8 Bot + Backup
Run by University of Colorado, Denver · NCT06324981 · Data updated 2026-11-12
This study is testing whether different types of text messages, including ones from an AI chatbot and support from a pharmacist, can help people at higher risk for heart disease improve their heart health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 89 Years |
| Sex | All |
| Enrollment | 2100 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 3 sites (Denver, Colorado and 2 other locations) |
| Status | Recruiting |
| Started | February 26, 2024 |
| Main results expected | February 2028 |
| Study ends | June 2028 |
| Registry record updated | March 22, 2024 |
| Trial ID | NCT06324981 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with hypertension, diabetes, or hyperlipidemia who exhibit poor adherence to their prescribed medication.
✕Probably not a fit
Patients who do not own a cellphone or are enrolled in hospice or palliative care may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of three different strategies—generic text messages, interactive AI chatbot messages, and chatbot messages with proactive pharmacist support—in reducing cardiovascular disease risk factors among patients facing health disparities. The study focuses on the American Heart Association's Life's Essential 8 factors, which include blood glucose, cholesterol, blood pressure, physical activity, body mass index, diet, and smoking. By engaging patients in self-management through technology, the trial seeks to improve health outcomes for those disproportionately affected by cardiovascular diseases.
Why it matters
Potential benefit: If successful, this approach could significantly enhance self-management of cardiovascular risk factors in underserved populations.
How similar studies have gone: Previous studies have shown that text messaging can positively impact self-management behaviors, suggesting potential success for this innovative approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of one or more of the following CV risk factors (i.e., hypertension, diabetes or hyperlipidemia); and * the risk factor is at poor or intermediate health levels as defined by LE8 (e.g., BP\>140/90 mm Hg); and * the patient exhibits poor adherence to prescribed medication to treat the CV risk factor as defined by a delay in refilling the medication within the past 6 months. Exclusion Criteria: * patients who do not have cellphone; or * enrolled in hospice or palliative care; or * Non-English or Spanish speaking; or * enrolled in another clinical trial if denoted in the EHR.
Where it's running
-
Denver Health
Denver, Colorado, United States Recruiting -
Salud Family Health Centers
Fort Lupton, Colorado, United States Not yet recruiting -
STRIDE Community Health Centers
Wheat Ridge, Colorado, United States Not yet recruiting
Study contacts
- Principal investigator: P. Michael Ho, MD PhD — University of Colorado, Denver
- Study coordinator: Lisa Sandy, MA
- Email: lisa.sandy@cuanschutz.edu
- Phone: 570-594-1564
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Digital lifestyle intervention to prevent cardiovascular disease
This study tests if a digital program can help people aged 40-60 in Sweden make healthier lifestyle choices to prevent heart disease.
-
Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery
This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.